This article is reprinted from the WeChat Official Account: Cell and Gene Therapy FieldRecently, several companies in China focusing on the cell and gene therapy (CGT) field have announced financing progress. This article will share basic information on five of these companies based on publicly available data.
1、Celregen Therapeutics Completes Nearly RMB100 Million Angel+ Round Financing, Focusing on Cell Therapy and Regenerative Medicine
Recently, Celregen Therapeutics successfully completed an angel+ round of financing worth nearly 100 million RMB. This round of financing was jointly participated by Fosun Pharma's New Drug Innovation Fund and Venture Creation Investment, aiming to support the company in its...Induced Pluripotent Stem Cell (iPSC) Regenerative Medicine PlatformThe further development on the platform will accelerate its clinical translation process in the fields of metabolic diseases and ophthalmic disease treatments.
Celregen Therapeutics was founded in 2022 and has been committed to exploring new treatment methods through innovations in regenerative medicine technology. The company focuses particularly on developing organ transplantation alternatives based on induced pluripotent stem cells (iPSC), aiming to provide more effective and safer treatment options for patients in need of organ transplants. The market prospects for iPSC-based regenerative medicine are broad, driven by both technological breakthroughs and clinical demands. iPSC technology generates pluripotent stem cells by reprogramming adult cells, which can differentiate into over 200 cell types such as cardiac muscle, neurons, and islet cells. This technology offers a stable source, low risk of immune rejection, and no ethical controversies. In terms of market potential, the global iPSC therapy market size is projected to reach $5.2 billion by 2028, with the Asia-Pacific region leading at an annual compound growth rate of 10.4%. In recent years, there has been significant capital enthusiasm for the iPSC sector, with global related financing exceeding $8 billion in 2024, accelerating the commercialization of this technology.
2、Saiqiao Ark Completes B+ Round Financing, Focusing on Cell and Gene Therapy Industry
Recently, Saiqiao Ark (Shenzhen) Biotechnology Co., Ltd. (hereinafter referred to as "Saiqiao Biotechnology")Announced the completion of its B+ round of financing, with investors being Fosun Health Capital and Changzhou High-Tech Investment.The financing funds willTo further promote Saiqiao Ark (Shenzhen) Biotechnology Co., Ltd.'s technology research and development and market expansion.。Saiqiao Ark (Shenzhen) Biotechnology Co., Ltd. was established in March 2020. The company is committed to mastering the initiative and pricing power in the industry's development through source technological innovation and the localization of key upstream manufacturing technologies and complete sets of core equipment for cell and gene therapy (CGT). It aims to achieve "one-click preparation + one-click release" for cell and gene drugs, pushing cell and gene therapies for cancer and chronic diseases from the million-yuan range into the ten-thousand-yuan era, benefiting a wider range of patients.
3、Nucleic Acid Drug CompanyRona Therapeutics Completes Over 100 Million Yuan Pre-B Round Financing
On March 14, 2025, Rona Therapeutics (Shanghai) Co., Ltd. ("Rona Therapeutics") announced the successful completion of its Pre-B round of financing, raising US$25 million (approximately RMB 180 million). This round of financing was led by Guanghua Wutong, with participation from new and existing shareholders including Lilly Asia Ventures, Jiangyuan Investment, and Boyuan Capital, fully demonstrating continued recognition and confidence in Rona Therapeutics' innovation in the nucleic acid drug field.
Rona Therapeutics is a global leading nucleic acid innovative drug platform company, focusing on the treatment of metabolic diseases, weight loss, and other related conditions. Rona Therapeutics is committed to developing differentiated and innovative best-in-class and first-in-industry siRNA drugs to address unmet clinical needs and improve treatment outcomes for cardiovascular diseases, obesity, and metabolic disorder-associated nonalcoholic steatohepatitis (NASH). Additionally, Rona Therapeutics is fully unlocking the enormous potential of extrahepatic delivery technologies for applications such as fat and muscle delivery, targeting various metabolic syndromes.
Recently, Shanghai Yufang Biomedical Technology Co., Ltd. (hereinafter referred to as "Yufang Bio") announced the completion of a Pre-A round of financing exceeding 100 million yuan. This round of financing was led by Guofang Innovation, with co-investments from Hongke Baishi, Feibiao Xiayan, Jiangbei Science and Technology Investment, and senior biomedical industry expert Wu Yu (Henry WU). Existing shareholders, Shanghai Biomedical Innovation Transformation Fund under Shanghai Industrial Capital and Shanghai Jinpu Muhe Fund, continued their support. The funds will be used to advance the clinical development of Yufang Bio's core cardiac gene therapy pipeline, JV101, and expand research into multiple heart failure indications.
Yufang Biotech was founded in 2021, focusing on the research and development of gene therapy drugs. Leveraging its self-developed next-generation telomere precision regulation technology platform, the company develops gene therapy drugs targeting major indications such as cardiovascular, neurological, and renal diseases from the perspective of aging. These efforts aim to meet significant unmet clinical needs and extend human lifespan. The company’s first indication focuses on heart failure that is unresponsive to standard drug treatments, leading to the development of JV101, an original "global new" gene therapy drug that targets telomeres in cardiac muscle cells. This drug effectively restores telomere homeostasis, regenerates mitochondria to restore cardiac muscle cell function, and reverses the progression of heart failure. After an Investigator-Initiated Trial (IIT) involving multiple patients with dilated cardiomyopathy (DCM) and heart failure, the company preliminarily verified the safety and efficacy of the drug in humans. Patients experienced a reversal in cardiac function, a significant reduction in cardiovascular risk events, and a marked improvement in quality of life. Compared with existing heart failure therapies, JV101 demonstrates clear technological leadership and broad clinical application prospects.5、Kunshi Biotech Completes Pre-A+ Round Financing
Recently, Kunshi Biotechnology, which focuses on macrophage-based drug treatments for solid tumors, announced that it has completedPre-A+ round of financing, which was solely invested by Qingdao Yinghai Antai Equity Investment Partnership (Limited Partnership),The funds will help advance the research and commercialization process of multiple products from the company.
Kunshi Biotech is a biotechnology company focused on the research, development, and production of macrophage-targeted drugs for solid tumors, actively promoting the industrialization of macrophage drugs in the field of targeted solid tumors. The company has a multi-pipeline layout, concentrating on the treatment of solid tumors, with indications covering 90% of solid tumors. Its lead pipeline, RR-M01, is a third-generation chimeric antigen receptor macrophage drug independently developed for HER2-positive solid tumors. Its indications include recurrent and refractory solid tumors such as HER2-positive ovarian cancer, gastric cancer, breast cancer, cervical cancer, endometrial cancer, lung cancer, and pancreatic cancer.In order to allow everyone to learn and communicate with each other better,WeChat Official Account "Cell Gene Therapy" TeamA WeChat group for cell therapy and gene therapy discussions has been established. Interested friends can scan the QR code below to add the editor's WeChat and join the cell therapy and gene therapy discussion group.。Article Recommendation (Click on the article title below to open the original text):
Covering a construction area of over 50,000 square meters, this project promotes the development of biopharmaceutical research in areas such as cell and gene therapy, aiming to create a world-class center for cell science! Another national major project has commenced construction.
World's First! iPS Cell Therapy Enables Paralyzed Patient to Stand Again
Up to 5 Million Yuan for a Single Project! Shanghai Releases the 2025 Key Technology R&D Plan "Cell and Gene Therapy" Project Application Guidelines
A Cell Therapy Company Lays Off 90%, Halts Core R&D Projects
Gimerix Cell Therapy Project Lands in Hainan, Completing the First Stem Cell Treatment Application in Lecheng!
Five Companies in China Complete New Round of Financing, Focusing on Cell and Gene Therapy Fields
First Global Phase 1 Clinical Trial of TIL Cell Therapy for All Types of Liver Cancer Reports Positive Results
$1 Billion! An In Vivo Cell Therapy Company Acquired
A Company in China Completes B+ Round Financing, Focusing on Cell and Gene Therapy Industry
Total Investment Reaches 10 Billion, Focusing on Cell Therapy and Other Industries, as a Biomedical City Project in China Breaks Ground
New Directions at the Two Sessions: The Trillion-Dollar Exosome Blue Ocean – How to Break Through Mass Production Bottlenecks and Reshape the Future of Healthcare
The World's First Exosome Cell Therapy Expected to Receive Rapid Approval for Market Launch This Year!
NMPA Approves First Mesenchymal Stromal Cell Drug for Clinical Use
China’s First CIK Cell Therapy Commercialization Imminent! Yantai Biotech’s Solid Tumor Cell Therapy Proposed for Priority Review
China's First Stem Cell Drug for Autism Approved for Clinical Trials
Gene therapy company Huayi Lejian, founded by Rao Yi, officially launches Phase III clinical trial for its first AAV gene drug
The World’s First Circular RNA Therapy Approved by the FDA for Clinical Trials Completes First Patient Dosing!
iPSC-Derived Corneal Cell Therapy Breaks Through Clinical Bottlenecks, Bringing Hope to Tens of Millions of Patients Worldwide
Disclaimer: This article is intended for knowledge sharing. All content is for reference only and does not constitute any advice.
